Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today the
initiation of the first of two planned pivotal phase 3 clinical trials
evaluating the safety and efficacy of 3.0 and 6.0 mg plecanatide,
once-daily oral tablets, for the treatment of irritable bowel syndrome
with constipation (IBS-C). Synergy is also evaluating 3.0 and 6.0 mg
doses of plecanatide in two ongoing pivotal phase 3 trials for chronic
idiopathic constipation (CIC), scheduled to read out top-line results in
second quarter and third quarter 2015.
By Philip van Doorn, MarketWatch These companies had double-digit increases in sales per share even before November's solid retail-sales report
After disappointing retail-sales reports around Thanksgiving, investors cheered on Thursday, when the Department of Commerce said U.S. retail sales rose 0.7% during November, the best performance in eight months.
Sign-up for HAWAIIAN ELECTRIC INDUSTRIES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Hawaiian Electric Industries, Inc. investment picks
Allianz Global Investors Fund Management LLC (the “Investment Manager")
announced today that Fund Cards, which contain statistical information
on the funds listed below as of September 30, 2014, are now available at http://us.allianzgi.com/Literature/Pages/ClosedEndFunds.aspx?ProductLineID=CEF&Level1=ulLiterature&Center=ulLiterature&Level2=liulLiteratureClosedEndFunds
The Investment Manager is an indirect, wholly-owned subsidiary of
Allianz Asset Management of America L.P., a member of Munich-based
Myers Industries, Inc. (NYSE:MYE), an international manufacturer of
polymer products and wholesale distributor servicing the under vehicle
service industry in the U.S., announced today that it has entered into a
definitive agreement to sell its Lawn & Garden business for $115 million
to an entity controlled by Wingate Partners V, L.P., a Dallas, TX based
private equity firm.
FOSTER CITY, CA --
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.